Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › pancreatic adenocarcinoma

Pancreatic adenocarcinoma

Part of Cancer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for pancreatic adenocarcinoma

28 trials tracked for pancreatic adenocarcinoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 13 citations.

28Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 19 Phase 1 2 Other / NA 4
  1. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  2. Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC Completed · 3 cited
  3. Phase 3 EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Completed
  4. Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Completed
  5. Phase 2 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Completed
  6. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
Show 22 more trials
  1. Phase 2 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Completed
  2. Phase 2 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Completed
  3. Phase 2 Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Completed
  4. Phase 2 Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  5. Phase 2 Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma Completed
  6. Phase 2 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Completed
  7. Phase 2 Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer Completed
  8. Phase 2 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Completed
  9. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Completed
  10. Phase 2 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Completed
  11. Phase 2 Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma Completed
  12. Phase 2 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Completed
  13. Phase 2 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer Completed
  14. Phase 2 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Completed
  15. Phase 2 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  16. Phase 2 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Completed
  17. Phase 1 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed
  18. Phase 1 Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Completed
  19. N/A Pancreatic Juice Diagnosis From Duodenum Completed
  20. N/A Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer Completed
  21. N/A 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation Completed
  22. N/A The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Pancreatic adenocarcinoma: what the trials found

Several chemotherapeutic agents have been evaluated for pancreatic adenocarcinoma. Capecitabine demonstrated comparable overall survival rates in both Phase II and Phase III assessments (p=0.62, p=0.38) 4. Gemcitabine was also studied, showing no significant difference in overall survival (p=0.72) or progression-free survival (p=0.91), while objective response rates varied across study arms (p=0.28) 15.

Fluorouracil has been evaluated in multiple trials; results showed no statistically significant difference in overall survival (p=0.15) 14, and a 42% R0 resection rate was observed at the two-year mark with an overall survival rate of 79% at one year 17. Nab-paclitaxel demonstrated varying objective response rates across different study groups, but showed consistent disease control in several cohorts (ranging from 55.6% to 81.3%) 7.

The EndoTAG-1 regimen did not show statistically significant differences in overall survival (p=0.6647), progression-free survival (p=0.4345), or objective response rates (p=0.2632) 6. Additionally, the use of eryaspase has been established in clinical trials for this condition 5.

Recent results — preliminary, needs further review

  • Paricalcitol (Zemplar) was associated with a significant reduction in serum levels of Carbohydrate Antigen 19-9 (CA19-9) (p=0.001) 1.
  • Paclitaxel Protein Bound (Abraxane) showed a statistically significant difference in R0 resection rates (p=0.017), though results for CA19-9 normalization and pathologic complete response were not statistically significant 2.
  • EUS FNA was evaluated as an intervention in recent clinical study 3.

For the clinician treating this condition

  • Standard chemotherapies including Capecitabine, Gemcitabine, and Fluorouracil have been established but did not show statistically significant improvements in survival metrics compared to respective controls in the reported trials.
  • Nab-paclitaxel demonstrated consistent disease control across multiple study arms 7.
  • Paricalcitol showed a statistically significant reduction in CA19-9 levels 1, and Abraxane showed a statistically significant difference in R0 resection rates 2.

AI synthesis of 10 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence
Oncology Meta-analysis
Splenic hilum nodal involvement is rare in pancreatic body adenocarcinoma with a 1.1% prevalence Nodal Involvement Near the Spleen Linked to Pancreatic Cancer
This meta-analysis of 2260 patients evaluates the prevalence of splenic hilum and splenic artery nodal involvement in pancreatic ductal aden…
New data shows that while certain lymph nodes near the spleen are often involved in pancreatic cancer, they may not change survival outcomes…
Sep 12, 2026
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients
Nutrition & Obesity Medicine Cohort
Dietary patterns associated with treatment outcomes in Stage III–IV pancreatic adenocarcinoma patients Diet patterns linked to outcomes in advanced pancreatic cancer patients
This retrospective observational study examined 210 patients with Stage III–IV pancreatic adenocarcinoma using real-world electronic medical…
Dietary patterns show links to treatment response and survival in advanced pancreatic cancer patients treated in real-world clinical setting…
Frontiers Apr 13, 2026

Research across Cancer

Related studies from across the Cancer family.

Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection
Oncology Guideline
Spatial immune-ecology framework proposed for gastric and GEJ adenocarcinoma ICI selection Spatial Features Help Map Immune Responses in Stomach Cancer
This narrative guideline review proposes a spatial immune-ecology framework for advanced gastric and gastroesophageal junction adenocarcinom…
New research maps how the immune system interacts with stomach and esophageal cancer to help experts understand why some treatments work bet…
Frontiers Sep 13, 2026
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma
Oncology Meta-analysis
CLDN18.2 expression prevalence of 33.99% in patients with gastric and gastroesophageal junction adenocarcinoma New data shows how many stomach cancer patients have target protein
This meta-analysis of 12,173 patients with gastric or gastroesophageal junction adenocarcinoma identified a pooled prevalence of CLDN18.2 ex…
A large review helps doctors understand how many stomach cancer patients have a specific protein that could be a target for new treatments.
Sep 6, 2026
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma
Gastroenterology Meta-analysis
Local therapies for liver, lung, and locoregional recurrence improve survival in pancreatic ductal adenocarcinoma Local Treatments May Improve Survival for Patients with Recurring Pancreatic Cancer
This meta-analysis of 22 studies evaluated local therapies versus conventional management for single-site recurrent pancreatic ductal adenoc…
New data suggests that local treatments like surgery can significantly improve survival for patients whose pancreatic cancer has returned.
Sep 1, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors
Oncology Sys. Review
KRAS G12C inhibitors may remodel immunosuppressive tumor microenvironments into immunostimulatory states in KRAS-mutant tumors Targeted Drugs May Help Change Immune Environment in KRAS Tumors
This mini-review examines the impact of KRAS mutations and G12C inhibitors on the tumor immune microenvironment across PDAC, CRC, and LAC. T…
New research suggests that specific drugs targeting KRAS mutations may help reshape the immune environment around certain types of cancer.
Frontiers Aug 27, 2026
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers
Allergy & Immunology Sys. Review
Immune checkpoint inhibitors show limited activity in unselected pancreatic ductal adenocarcinoma without specific biomarkers New Strategies Target Immune Therapies for Pancreatic Cancer
This mini review examines the role of immune checkpoint blockade, vaccines, and cellular therapies in recurrent pancreatic ductal adenocarci…
New research highlights specific ways to better select patients for immune checkpoint inhibitors and advanced cell therapies in pancreatic c…
Frontiers Aug 14, 2026
AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Frontiers Jul 18, 2026
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Frontiers Jun 24, 2026
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Frontiers May 30, 2026
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Frontiers May 28, 2026
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Frontiers May 24, 2026
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male
Rheumatology Meta-analysis
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male A 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition
This case report and literature review examines a 70-year-old male patient with IgG4-related autoimmune pancreatitis initially suspected as …
A 70-year-old man with a pancreatic mass was found to have a treatable autoimmune disease, sparing him from unnecessary surgery.
Frontiers May 17, 2026